The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 11, 2004, Pages 1219-1227

  Dumez, Herlinde ^a   Guetens, Gunther ^a,b   De Boeck, Gert ^a   Highley, Martin S ^c   Maes, Robert A A ^d   van Oosterom, Allan T ^a   de Bruijn, Ernst A ^a  

^a Laboratory of Experimental Psychology   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anti cancer drugs; Erythrocyte; Measurement of sediment

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYTARABINE; DOXIFLURIDINE; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; HEXAMETHYLENEBISACETAMIDE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; MUSTARD GAS DERIVATIVE; OXAZAPHOSPHORINE DERIVATIVE; PLATINUM DERIVATIVE; PODOPHYLLOTOXIN; SURAMIN; TENIPOSIDE; THIOGUANINE DERIVATIVE; VINCRISTINE;

ACIDOSIS; ANALYTIC METHOD; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERYTHROCYTE LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TOXICITY; DRUG TRANSPORT; GAS CHROMATOGRAPHY; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIQUID CHROMATOGRAPHY; LIVER METASTASIS; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS; DRUG MONITORING; ERYTHROCYTES; HUMANS; MASS SPECTROMETRY; MONITORING, PHYSIOLOGIC; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 10044282574     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.244     Document Type: Article

References (67)

1. de Bruijn EA. Monitoring anticancer drugs, 2nd ed., 1994 (3rd ed. in press).
2. Guetens G, De Boeck G, Highley M, Dumez H, van Oosterom AT, de Bruijn EA. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. J Chromatogr A 2003;1020:27-34.
3. Tjaden UR, de Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr 1990;531:235-94.
4. Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987;13:205-27.
5. Ratain MJ. Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol 1992;19:8-13.
6. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16:327-36.
7. Kobayashi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993;20:30-42.
8. Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem 1993;39:2419-30.
9. de Bruijn EA. Therapeutic drug monitoring and cancer treatment: sense and nonsense. In press.
10. de Bruijn EA, Kuppen PJK, Leeflang P, Slee P, van Oosterom AT. Constructing an in vitro area under the curve for testing antitumour agents with the mean residence time as starting point. Br J Pharmacol 1986;89:510.
11. Slee PH, Van Oosterom AT, de Bruijn EA. Predictive testing in cancer chemotherapy. I. In vivo. Pharm Weekbl Sci 1985;7:93-9.
12. Slee PH, Van Oosterom AT, De Bruijn EA. Predictive testing in cancer chemotherapy. II. In vitro. Pharm Weekbl Sci 1985;7:125-33.
13. Dumez H, Reinhart WH, Guetens G, de Bruijn EA. Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugs. Crit Rev Clin Lab Sci 2004;41:159-88.
14. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
15. Longo DL, Duffey PL, DeVita VT Jr, Wesley MN, Hubbard SM, Young RC. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991;9:2042-51.
16. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-70.
17. Tjaden UR, Reeuwijk HJ, van der Greef J, Pattyn G, de Bruijn EA, Van Oosterom AT. Bioanalysis of suramin in human plasma by ion-pair high-performance liquid chromatography. J Chromatogr 1990;26:141-9.
18. Highley MS, de Bruijn EA. Erythrocytes and the transport of drugs and endogenous compounds. Pharm Res 1996;13:186-95.
19. Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213-42.
20. Slee PH, de Bruijn EA, Driessen OM, Hermans J, van Oosterom AT. Pharmacokinetics of the cytostatic drugs used in the CMF regimen. Anticancer Res 1983;3:269-7.
21. de Bruijn EA, Driessen O, Leeflang P, van Strijen E, van den Bosch N, Hermans J. Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model. Cancer Treat Rep 1987;71:1267-9.
22. de Bruijn EA, Driessen O, Leeflang P, van den Bosch N, van Strijen E, Slee PH, Hermans J. Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in an animal model. Cancer Treat Rep 1986;70:1159-65.
23. De Bruijn EA, Geng Y, Hermans J, Driessen O. The CMF regimen. Modulation of cyclophosphamide uptake and clearance by methotrexate and fluorouracil. Int J Cancer 1990;15:935-9.
24. Gheuens E, Slee PH, de Bruijn EA. Bioavailability of cyclophosphamide in the CMF regimen. Onkologie 1990;13:203-6.
25. Evans WE, Petros WP, Relling MV, Crom WR, Madden T, Rodman JH, Sunderland M. Clinical pharmacology of cancer chemotherapy in children. Pediatr Clin North Am 1989;36:1199-230.
26. Evans WE, Relling MV, Rodman JH, Crom WR. Anticancer therapy as a pediatric pharmacodynamic paradigm. Dev Pharmacol Ther 1989;13:85-95.
27. McLeod HL, Relling MV, Crom WR, Silverstein K, Groom S, Rodman JH, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992;18:23-9.
28. Rodman JH, Relling MV, Stewart CF, Synold TW, Mc-Leod H, Kearns C, et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993;20:18-29.
29. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993;20:43-9.
30. Evans WE, Rodman JH, Relling MV, Crom WR, Rivera GK, Pratt CB, et al. Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 1991;19:153-9.
31. Guetens G, De Boeck G, Wood M, Maes RA, Eggermont AA, Highley MS, et al. Hyphenated techniques in anticancer drug monitoring. I. Capillary gas chromatography-mass spectrometry. J Chromatogr A 2002; 976:229-38.
32. Guetens G, De Boeck G, Highley MS, Wood M, Maes RA, Eggermont AA, et al. Hyphenated techniques in anticancer drug monitoring. II. Liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry. J Chromatogr A 2002;976:239-47.
33. Hall SW, Friedman J, Legha SS, Benjamin RS, Gutterman JU, Loo TL. Human pharmacokinetics of a new acridine derivative, 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992). Cancer Res 1983;43:3422-6.
34. Rustum YM, Riva C, Preisler HD. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. Semin Oncol 1987;14:141-8.
35. Preisler HD, Rustum Y, Priore RL. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Eur J Cancer Clin Oncol 1985;21:23-30.
36. Preisler HD, Rustum YM, Azarnia N, Priore R. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside. Cancer Chemother Pharmacol 1987;19:69-74.
37. Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy. Cancer Res 1979;39:42-9.
38. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987;47:1952-6.
39. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 1991;50:385-93.
40. Goldberg JA, Kerr DJ, Willmott N, McKillop JH, McArdle CS. Pharmacokinetics and pharmacodynamics of loco-regional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer 1988;57:186-9.
41. Milano G, Roman P, Khater R, Frenay M, Renee N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988;41:537-41.
42. Milano G, Namer M, Boublil JL, Khater R, Frenay M, Thyss A, et al. Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy. Cancer Chemother Pharmacol 1987;20:71-4.
43. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989;59:287-90.
44. Au JL, Rustum YM, Ledesma EJ, Mittelman A, Creaven PJ. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res 1982;42:2930-7.
45. Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 1991;9:2027-35.
46. de Bruijn EA, van Oosterom AT, Tjaden UR, Reeuwijk HJ, Pinedo HM. Pharmacology of 5′-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res 1985;45:5931-5.
47. Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, et al. Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemother Pharmacol 1992;31:37-45.
48. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983;16:359-63.
49. Zimm S, Reaman G, Murphy RF, Poplack DG. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 1986;46:1495-8.
50. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986;40:287-92.
51. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-23 (erratum in: J Clin Oncol 1990;8:567).
52. Borsi JD, Moe PJ. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 1987;15:3020-4.
53. Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1984;18:359-62.
54. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986;314:471-7.
55. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979;3:161-6.
56. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297:630-4.
57. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutane-dicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984;44:5432-8.
58. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
59. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum(II) analogue diammine cyclobutane dicarboxylato platinum. Cancer Res 1985;45:6502-6.
60. Horwich A, Dearnaley DP, Nicholls J, Jay G, Mason M, Harland S, et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 1991;9:62-9.
61. Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983;67:169-72.
62. Rodman JH, Abromowitch M, Sinkule JA, Hayes FA, Rivera GK, Evans WE. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol 1987;5:1007-14.
63. Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. J Pharmacol Exp Ther 1992;260:71-7.
64. Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. J Clin Oncol 1993;11:287-93.
65. Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982;8:211-4.
66. Van Der Heyden SA, Highley MS, de Bruijn EA, Tjaden UR, Reeuwijk HJ, Van Slooten H, et al. Pharmacokinetics and bioavailability of oral 5′-deoxy-5-fluorouridine in cancer patients. Br J Clin Pharmacol 1999;47:351-6.
67. Tomita M, Aoki Y, Tanaka K. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. Clin Pharmacokinet 2004;43:515-27.